Feb 23 (Reuters) - EMA:

* EMA SAYS CHMP COMPLETED A REVIEW OF IBUPROFEN NVT FOLLOWING A DISAGREEMENT AMONG EU MEMBER STATES REGARDING ITS AUTHORISATION

* EMA, ON IBUPROFEN NVT REVIEW, SAYS CONCLUDED THAT THE BENEFITS OF THIS MEDICINE DO NOT OUTWEIGH ITS RISKS

* EMA, ON IBUPROFEN NVT, SAYS MARKETING AUTHORISATIONS IN LITHUANIA AND OTHER MEMBER STATES WHERE MEDICINE IS AUTHORISED SHOULD BE SUSPENDED

* EMA: CHMP ADOPTED POSITIVE OPINIONS FOR TWO VACCINES CELLDEMIC AND INCELLIPAN FOR ACTIVE IMMUNISATION AGAINST THE H5N1 SUBTYPE OF INFLUENZA A VIRUS

* EMA: CHMP GAVE POSITIVE OPINION FOR VOYDEYA (DANICOPAN),ORAL TREATMENT AGAINST RESIDUAL HAEMOLYTIC ANAEMIA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)